Galderma delivers record net sales of 3.737 billion USD in the first nine months of 2025 and 15.0% year-on-year growth at constant currency, raises full-year guidance Press release
Galderma delivers record first half 2025 net sales of 2.448 billion USD and 12.2% year-on-year growth at constant currency, raises full-year top-line guidance Press release
Galderma buys back shares worth CHF 233 million in the context of accelerated bookbuild offering Press release
Galderma intends to buy back approximately 2.4 million shares in the context of the accelerated bookbuild offering by EQT, ADIA and Auba Press release
Galderma delivers record first quarter net sales of 1.129 billion USD, including strong performance from two launches with blockbuster potential, and confirms full-year guidance Press release
Galderma publishes its 2024 Annual Report and the invitation to its first Annual General Meeting Press release
Galderma delivers 2024 record net sales of 4.410 billion USD, up 9.3% year-on-year at constant currency1, and record Core EBITDA of 1.031 billion USD, while preparing to accelerate its growth trajectory into 2025 and beyond Press release
Galderma’s Nemluvio® (nemolizumab) approved in the European Union for moderate-to-severe atopic dermatitis and prurigo nodularis Press release
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis Press release
